Legend Biotech Corp (LEGN) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US52490G1022

Legend Biotech Corp (NASDAQ: LEGN) is a clinical-stage biopharmaceutical company specializing in the development and production of innovative cell therapies for oncology and other medical indications globally.

The company's flagship product, LCAR-B38M, is a unique chimeric antigen receptor designed for treating multiple myeloma (MM), a specific form of cancer.

In addition to its primary product, Legend Biotech Corp features a diverse range of autologous CAR-T product candidates at various developmental stages. These potential therapies target a wide spectrum of cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.

Established in 2014 and headquartered in Somerset, New Jersey, Legend Biotech Corp operates globally, with a strong presence in the United States and China.

Moreover, Legend Biotech Corp has entered into strategic collaboration and licensing agreements, such as the partnership with Janssen Biotech, Inc., focusing on the development and commercialization of ciltacabtagene autoleucel, further expanding its reach and impact in the field of biopharmaceuticals.

For more information on Legend Biotech Corp, visit their official website at https://www.legendbiotech.com.

AI improved, may contain errors or wrong assumptions

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Legend Biotech Corp (LEGN) - Stock & Dividends

LEGN Stock Overview

Market Cap in USD 11,114m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2020-06-05

LEGN Stock Ratings

Fundamental -5.22
Dividend -
Growth 5y 4.77
Rel. Performance vs Sector 1.92
Analysts 4.22
Fair Price Total Ret. 66.15
Fair Price DCF -

LEGN Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

LEGN Growth Ratios

Growth 12m 51.56%
Growth Correlation 12m -16%
Growth Correlation 3m -22%
CAGR 5y 18.60%
CAGR / Mean Drawdown 0.98
Sharpe Ratio 12m 1.07
Alpha vs SP500 12m 22.67
Beta vs SP500 5y weekly 0.96
CAPM 7.89%
Average Daily Range 2m 4.07%
Regime Oscillator 96.00
Volatility GJR Garch 1y 46.38%
Price / SMA 50 17.95%
Price / SMA 200 6.95%
Current Volume 1165.1k
Average Volume 20d 773.8k

External Links for LEGN Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of LEGN stocks?
As of February 28, 2024, the stock is trading at USD 69.99 with a total of 1,165,078 shares traded.
Over the past week, the price has changed by +16.46%, over one month by +23.77%, over three months by +13.69% and over the past year by +51.10%.
Why is LEGN stock down?
Check with which Index or Commodity LEGN has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return LEGN Return S&P 500
1 Month 23.77% 4.00%
3 Months 13.69% 11.99%
12 Months 51.10% 29.39%
What is the forecast for LEGN stock price target?
According to ValueRays Forecast Model, LEGN Legend Biotech Corp will be worth about 73.6 in February 2025. The stock is currently trading at 69.99. This means that the stock has a potential upside of +5.14%.
Issuer Forecast Upside
Wallstreet Target Price 86.3 23.3%
Analysts Target Price 88.4 26.2%
ValueRay Target Price 73.6 5.1%